Clinical trials: 5-FU, completed
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill more tumor cells.
- Trial name
- NCT00026273
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in Austria, Belgium and 8 more
- Sponsor
- Pfizer
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cryosurgery kills cancer cells by freezing them.
- Trial name
- NCT00008294
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Adenocarcinoma of the Rectum, Stage II Rectal Cancer
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
This phase I trial is studying the side effects and best dose of bevacizumab when given together with fluorouracil and external-beam radiation therapy in treating patients with stage II or stage III rectal cancer.
- Conditions
- Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
- Trial name
- NCT00052559
- Testing
- bevacizumab, fluorouracil, external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Oropharynx Cancer, Squamous Cell Carcinoma of the Oral Cavity
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer.
- Trial name
- NCT01108042
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 4 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Orlando Guntinas-Lichius, Prof. Dr. med.
Metastatic Colorectal Cancer, Chemotherapy Effect
Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer
This is a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy and safety of rechallenge chemotherapy in the third or later-line treatment in patients with advanced colorectal cancer.
- Trial name
- NCT03485027
- Testing
- the rechallenge regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin®) plus mXELIRI compared with bevacizumab…
- Trial name
- NCT04247984
- Testing
- Bevacizumab, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Chinese Academy of Medical Sciences
Myocardial Infarction
ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction
The purpose of this study is to evaluate whether perioperative use of Shenfu Injection could reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac magnetic resonance imaging) in patients with…
- Trial name
- SF-STEMI (NCT02709798)
- Testing
- Shenfu Injection, 5% Glucose Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Anzhen Hospital
Colorectal Neoplasm
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in combination with 5-FU…
- Trial name
- NCT02244632
- Testing
- Modufolin (arfolitixorin), Fluorouracil, Oxaliplatin
- Where
- 10 sites in Denmark, Greece and 2 more
- Volunteers
- 105 people
- Sponsor
- Isofol Medical AB
Advanced Pancreatic Cancer
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
- Trial name
- NCT04796948
- Testing
- Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
Colorectal Cancer Metastatic
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer
This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metastatic colorectal cancer.
- Trial name
- FOIB (NCT01163396)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Volunteers
- 57 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Kidney, Cancer
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment.
- Trial name
- NCT00277017
- Testing
- 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Gastrointestinal Cancer Metastatic, Renal Cell Cancer Metastatic
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in…
- Conditions
- Gastrointestinal Cancer Metastatic, Renal Cell Cancer Metastatic, Non Small Cell Lung Cancer Metastatic
- Trial name
- NCT01658813
- Testing
- 5-Fluorouracil and Interferon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Western Regional Medical Center
Advanced KRAS Positive Metastatic Colorectal Cancer
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of…
- Trial name
- NCT02613650
- Testing
- MEK162 and mFOLFIRI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Pancreatic Cancer
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
This is a phase II study of biweekly (every other week) bevacizumab followed by gemcitabine then infusional 5-fluorouracil in patients with stage III or IV pancreatic cancer.
- Trial name
- NCT00417976
- Testing
- Gemcitabine, Bevacizumab, Infusional 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Tony Bekaii-Saab
Rectal Neoplasms, Rectal Cancer Stage II
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
Preoperative 5-FU-based (5-fluorouracil) chemoradiotherapy (CRT), total mesorectal excision surgery, and 4 cycles of adjuvant 5-FU - as established by CAO/ARO/AIO-94 - is at present a standard of care for patients with locally…
- Conditions
- Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- CAOAROAIO-12 (NCT02363374)
- Testing
- Induction Chemotherapy arm A, Radiation arm A, Radiation arm B
- Where
- 20 sites in Germany
- Volunteers
- 311 people
- Sponsor
- Prof. Dr. med. Claus Rödel
Head and Neck Cancer
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy…
- Trial name
- NCT00716391
- Testing
- TPF, radiotherapy and cisplatin., TPF, radiotherapy and cetuximab.
- Where
- 39 sites in Spain
- Volunteers
- 519 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Head and Neck Cancer
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.
- Trial name
- EPIC (NCT00468169)
- Testing
- Cetuximab, 5-FU, Hydroxyurea
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Chicago
Unspecified Adult Solid Tumor, Protocol Specific
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00042861
- Testing
- 7-hydroxystaurosporine, fluorouracil, leucovorin calcium
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.